25 XP   0   0   10

BioNTech SE
Buy, Hold or Sell?

Let's analyse Biontech together

PenkeI guess you are interested in BioNTech SE. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioNTech SE. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BioNTech SE

I send you an email if I find something interesting about BioNTech SE.

Quick analysis of Biontech (30 sec.)










What can you expect buying and holding a share of Biontech? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
22.2%

What is your share worth?

Current worth
€83.57
Expected worth in 1 year
€91.47
How sure are you?
88.9%

+ What do you gain per year?

Total Gains per Share
€7.89
Return On Investment
9.3%

For what price can you sell your share?

Current Price per Share
€85.34
Expected price per share
€77.50 - €92.54
How sure are you?
50%

1. Valuation of Biontech (5 min.)




Live pricePrice per Share (EOD)

€85.34

Intrinsic Value Per Share

€358.72 - €421.22

Total Value Per Share

€442.29 - €504.79

2. Growth of Biontech (5 min.)




Is Biontech growing?

Current yearPrevious yearGrowGrow %
How rich?$21.4b$17b$4.6b21.3%

How much money is Biontech making?

Current yearPrevious yearGrowGrow %
Making money$743.9m$2.7b-$2b-275.2%
Net Profit Margin-0.8%54.8%--

How much money comes from the company's main activities?

3. Financial Health of Biontech (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#3 / 1031

Most Revenue
#10 / 1031

Most Profit
#6 / 1031

Most Efficient
#473 / 1031

What can you expect buying and holding a share of Biontech? (5 min.)

Welcome investor! Biontech's management wants to use your money to grow the business. In return you get a share of Biontech.

What can you expect buying and holding a share of Biontech?

First you should know what it really means to hold a share of Biontech. And how you can make/lose money.

Speculation

The Price per Share of Biontech is €85.34. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biontech.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biontech, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €83.57. Based on the TTM, the Book Value Change Per Share is €1.97 per quarter. Based on the YOY, the Book Value Change Per Share is €9.94 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biontech.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.730.9%0.720.8%11.5013.5%4.455.2%4.455.2%
Usd Book Value Change Per Share0.600.7%2.132.5%10.7512.6%5.025.9%5.025.9%
Usd Dividend Per Share0.000.0%0.000.0%1.621.9%0.480.6%0.480.6%
Usd Total Gains Per Share0.600.7%2.132.5%12.3714.5%5.506.4%5.506.4%
Usd Price Per Share109.47-124.14-176.48-114.50-114.50-
Price to Earnings Ratio37.45-43.00-4.15-3.77-3.77-
Price-to-Total Gains Ratio183.75-45.16-17.29-18.91-18.91-
Price to Book Ratio1.21-1.38-2.66-7.45-7.45-
Price-to-Total Gains Ratio183.75-45.16-17.29-18.91-18.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share92.312278
Number of shares10
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.48
Usd Book Value Change Per Share2.135.02
Usd Total Gains Per Share2.135.50
Gains per Quarter (10 shares)21.3555.02
Gains per Year (10 shares)85.39220.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10857519201210
2017116038402430
3025624558603650
4034233077804870
504274159610041090
6051250011512051310
7059858513414061530
8068367015416071750
9076975517318081970
10085484019220092190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%12.06.00.066.7%12.06.00.066.7%12.06.00.066.7%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%16.02.00.088.9%16.02.00.088.9%16.02.00.088.9%
Dividend per Share0.00.04.00.0%4.00.08.033.3%4.00.014.022.2%4.00.014.022.2%4.00.014.022.2%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%16.02.00.088.9%16.02.00.088.9%16.02.00.088.9%

Fundamentals of Biontech

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Fundamental data was last updated by Penke on 2024-03-09 23:11:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of BioNTech SE.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biontech earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • A Net Profit Margin of 17.9% means that €0.18 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioNTech SE:

  • The MRQ is 17.9%. The company is making a huge profit. +2
  • The TTM is -0.8%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ17.9%TTM-0.8%+18.7%
TTM-0.8%YOY54.8%-55.5%
TTM-0.8%5Y-41.1%+40.4%
5Y-41.1%10Y-41.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.9%-159.2%+177.1%
TTM-0.8%-202.3%+201.5%
YOY54.8%-263.0%+317.8%
5Y-41.1%-452.4%+411.3%
10Y-41.1%-589.0%+547.9%
1.1.2. Return on Assets

Shows how efficient Biontech is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • 0.7% Return on Assets means that Biontech generated €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioNTech SE:

  • The MRQ is 0.7%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 3.0%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.7%TTM3.0%-2.3%
TTM3.0%YOY13.5%-10.5%
TTM3.0%5Y6.2%-3.3%
5Y6.2%10Y6.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7%-12.5%+13.2%
TTM3.0%-12.2%+15.2%
YOY13.5%-11.2%+24.7%
5Y6.2%-13.3%+19.5%
10Y6.2%-14.6%+20.8%
1.1.3. Return on Equity

Shows how efficient Biontech is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • 0.8% Return on Equity means Biontech generated €0.01 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioNTech SE:

  • The MRQ is 0.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.8%TTM3.4%-2.6%
TTM3.4%YOY17.4%-14.0%
TTM3.4%5Y9.0%-5.5%
5Y9.0%10Y9.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8%-16.0%+16.8%
TTM3.4%-15.8%+19.2%
YOY17.4%-13.9%+31.3%
5Y9.0%-18.2%+27.2%
10Y9.0%-19.1%+28.1%

1.2. Operating Efficiency of BioNTech SE.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biontech is operating .

  • Measures how much profit Biontech makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • An Operating Margin of 11.1% means the company generated €0.11  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioNTech SE:

  • The MRQ is 11.1%. The company is operating less efficient.
  • The TTM is -49.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ11.1%TTM-49.2%+60.3%
TTM-49.2%YOY65.6%-114.8%
TTM-49.2%5Y-41.7%-7.5%
5Y-41.7%10Y-41.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.1%-299.5%+310.6%
TTM-49.2%-208.5%+159.3%
YOY65.6%-280.2%+345.8%
5Y-41.7%-459.9%+418.2%
10Y-41.7%-596.9%+555.2%
1.2.2. Operating Ratio

Measures how efficient Biontech is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.65 means that the operating costs are €1.65 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of BioNTech SE:

  • The MRQ is 1.645. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.590. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.645TTM2.590-0.945
TTM2.590YOY0.569+2.021
TTM2.5905Y1.837+0.753
5Y1.83710Y1.8370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6452.817-1.172
TTM2.5903.181-0.591
YOY0.5693.609-3.040
5Y1.8375.554-3.717
10Y1.8377.396-5.559

1.3. Liquidity of BioNTech SE.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biontech is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.37 means the company has €10.37 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of BioNTech SE:

  • The MRQ is 10.375. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.330. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.375TTM10.330+0.045
TTM10.330YOY4.976+5.354
TTM10.3305Y5.238+5.091
5Y5.23810Y5.2380.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.3753.987+6.388
TTM10.3304.440+5.890
YOY4.9765.569-0.593
5Y5.2386.158-0.920
10Y5.2386.492-1.254
1.3.2. Quick Ratio

Measures if Biontech is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • A Quick Ratio of 2.52 means the company can pay off €2.52 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioNTech SE:

  • The MRQ is 2.518. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.905. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.518TTM2.905-0.387
TTM2.905YOY2.864+0.041
TTM2.9055Y1.764+1.141
5Y1.76410Y1.7640.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5183.653-1.135
TTM2.9054.158-1.253
YOY2.8645.515-2.651
5Y1.7646.012-4.248
10Y1.7646.206-4.442

1.4. Solvency of BioNTech SE.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biontech assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biontech to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Biontech assets are financed with 10.5% credit (debt) and the remaining percentage (100% - 10.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioNTech SE:

  • The MRQ is 0.105. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.108. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.105TTM0.108-0.002
TTM0.108YOY0.215-0.107
TTM0.1085Y0.295-0.187
5Y0.29510Y0.2950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1050.336-0.231
TTM0.1080.330-0.222
YOY0.2150.267-0.052
5Y0.2950.367-0.072
10Y0.2950.378-0.083
1.4.2. Debt to Equity Ratio

Measures if Biontech is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.8% means that company has €0.12 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioNTech SE:

  • The MRQ is 0.118. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.121. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.118TTM0.121-0.003
TTM0.121YOY0.274-0.153
TTM0.1215Y0.463-0.341
5Y0.46310Y0.4630.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1180.376-0.258
TTM0.1210.398-0.277
YOY0.2740.334-0.060
5Y0.4630.431+0.032
10Y0.4630.476-0.013

2. Market Valuation of BioNTech SE

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Biontech generates.

  • Above 15 is considered overpriced but always compare Biontech to the Biotechnology industry mean.
  • A PE ratio of 37.45 means the investor is paying €37.45 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioNTech SE:

  • The EOD is 31.580. Based on the earnings, the company is overpriced. -1
  • The MRQ is 37.448. Based on the earnings, the company is overpriced. -1
  • The TTM is 43.000. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD31.580MRQ37.448-5.869
MRQ37.448TTM43.000-5.552
TTM43.000YOY4.154+38.846
TTM43.0005Y3.768+39.232
5Y3.76810Y3.7680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD31.580-2.697+34.277
MRQ37.448-2.422+39.870
TTM43.000-2.709+45.709
YOY4.154-4.116+8.270
5Y3.768-6.257+10.025
10Y3.768-6.478+10.246
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioNTech SE:

  • The EOD is 7.684. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 9.112. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 3.511. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD7.684MRQ9.112-1.428
MRQ9.112TTM3.511+5.601
TTM3.511YOY-11.216+14.727
TTM3.5115Y-16.929+20.440
5Y-16.92910Y-16.9290.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.684-3.344+11.028
MRQ9.112-2.939+12.051
TTM3.511-3.486+6.997
YOY-11.216-5.592-5.624
5Y-16.929-8.464-8.465
10Y-16.929-8.872-8.057
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biontech is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.21 means the investor is paying €1.21 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of BioNTech SE:

  • The EOD is 1.021. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.211. Based on the equity, the company is underpriced. +1
  • The TTM is 1.379. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.021MRQ1.211-0.190
MRQ1.211TTM1.379-0.168
TTM1.379YOY2.663-1.284
TTM1.3795Y7.447-6.068
5Y7.44710Y7.4470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.0212.198-1.177
MRQ1.2112.042-0.831
TTM1.3792.121-0.742
YOY2.6632.907-0.244
5Y7.4473.682+3.765
10Y7.4474.114+3.333
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BioNTech SE compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5511.974-72%9.940-94%4.643-88%4.643-88%
Book Value Per Share--83.57483.287+0%64.886+29%37.836+121%37.836+121%
Current Ratio--10.37510.330+0%4.976+108%5.238+98%5.238+98%
Debt To Asset Ratio--0.1050.108-2%0.215-51%0.295-64%0.295-64%
Debt To Equity Ratio--0.1180.121-3%0.274-57%0.463-75%0.463-75%
Dividend Per Share----0%1.496-100%0.443-100%0.443-100%
Eps--0.6760.668+1%10.630-94%4.115-84%4.115-84%
Free Cash Flow Per Share--2.7764.890-43%12.641-78%4.051-31%4.051-31%
Free Cash Flow To Equity Per Share--1.4683.596-59%11.195-87%3.771-61%3.771-61%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--421.220--------
Intrinsic Value_10Y_min--358.717--------
Intrinsic Value_1Y_max--27.547--------
Intrinsic Value_1Y_min--27.049--------
Intrinsic Value_3Y_max--93.941--------
Intrinsic Value_3Y_min--89.458--------
Intrinsic Value_5Y_max--173.808--------
Intrinsic Value_5Y_min--160.363--------
Market Cap20286683440.000-19%24056859200.00027623352977.650-13%39598289212.400-39%25578963978.442-6%25578963978.442-6%
Net Profit Margin--0.179-0.008+104%0.548-67%-0.411+329%-0.411+329%
Operating Margin--0.111-0.492+544%0.656-83%-0.417+477%-0.417+477%
Operating Ratio--1.6452.590-36%0.569+189%1.837-10%1.837-10%
Pb Ratio1.021-19%1.2111.379-12%2.663-55%7.447-84%7.447-84%
Pe Ratio31.580-19%37.44843.000-13%4.154+801%3.768+894%3.768+894%
Price Per Share85.340-19%101.200114.763-12%163.150-38%105.853-4%105.853-4%
Price To Free Cash Flow Ratio7.684-19%9.1123.511+160%-11.216+223%-16.929+286%-16.929+286%
Price To Total Gains Ratio154.949-19%183.74545.160+307%17.287+963%18.905+872%18.905+872%
Quick Ratio--2.5182.905-13%2.864-12%1.764+43%1.764+43%
Return On Assets--0.0070.030-76%0.135-95%0.062-88%0.062-88%
Return On Equity--0.0080.034-76%0.174-95%0.090-91%0.090-91%
Total Gains Per Share--0.5511.974-72%11.436-95%5.086-89%5.086-89%
Usd Book Value--21489917560.00021659474035.000-1%17037153595.000+26%9882740517.556+117%9882740517.556+117%
Usd Book Value Change Per Share--0.5962.135-72%10.752-94%5.022-88%5.022-88%
Usd Book Value Per Share--90.40290.092+0%70.187+29%40.927+121%40.927+121%
Usd Dividend Per Share----0%1.619-100%0.480-100%0.480-100%
Usd Eps--0.7310.723+1%11.498-94%4.451-84%4.451-84%
Usd Free Cash Flow--713922000.0001268266207.500-44%3319872512.500-78%1060750295.439-33%1060750295.439-33%
Usd Free Cash Flow Per Share--3.0035.289-43%13.673-78%4.382-31%4.382-31%
Usd Free Cash Flow To Equity Per Share--1.5883.890-59%12.109-87%4.079-61%4.079-61%
Usd Market Cap21944105477.048-19%26022304596.64029880180915.924-13%42833469441.053-39%27668765335.480-6%27668765335.480-6%
Usd Price Per Share92.312-19%109.468124.139-12%176.479-38%114.501-4%114.501-4%
Usd Profit--173721020.000743966217.500-77%2791299807.500-94%1206461354.978-86%1206461354.978-86%
Usd Revenue--968446010.0001789753777.500-46%5020386040.000-81%2355225072.333-59%2355225072.333-59%
Usd Total Gains Per Share--0.5962.135-72%12.370-95%5.502-89%5.502-89%
 EOD+4 -4MRQTTM+14 -19YOY+9 -265Y+13 -2210Y+13 -22

3.2. Fundamental Score

Let's check the fundamental score of BioNTech SE based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1531.580
Price to Book Ratio (EOD)Between0-11.021
Net Profit Margin (MRQ)Greater than00.179
Operating Margin (MRQ)Greater than00.111
Quick Ratio (MRQ)Greater than12.518
Current Ratio (MRQ)Greater than110.375
Debt to Asset Ratio (MRQ)Less than10.105
Debt to Equity Ratio (MRQ)Less than10.118
Return on Equity (MRQ)Greater than0.150.008
Return on Assets (MRQ)Greater than0.050.007
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of BioNTech SE based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.577
Ma 20Greater thanMa 5084.977
Ma 50Greater thanMa 10086.094
Ma 100Greater thanMa 20089.893
OpenGreater thanClose84.820
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets22,207,200
Total Liabilities2,340,400
Total Stockholder Equity19,866,800
 As reported
Total Liabilities 2,340,400
Total Stockholder Equity+ 19,866,800
Total Assets = 22,207,200

Assets

Total Assets22,207,200
Total Current Assets18,749,100
Long-term Assets3,458,100
Total Current Assets
Cash And Cash Equivalents 13,495,800
Short-term Investments 2,253,300
Net Receivables 2,298,100
Inventory 415,700
Other Current Assets 286,200
Total Current Assets  (as reported)18,749,100
Total Current Assets  (calculated)18,749,100
+/-0
Long-term Assets
Property Plant Equipment 925,900
Goodwill 365,600
Long Term Investments 1,292,700
Intangible Assets 665,500
Other Assets 208,400
Long-term Assets  (as reported)3,458,100
Long-term Assets  (calculated)3,458,100
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,807,200
Long-term Liabilities533,200
Total Stockholder Equity19,866,800
Total Current Liabilities
Short Long Term Debt 40,000
Accounts payable 222,700
Other Current Liabilities 1,544,500
Total Current Liabilities  (as reported)1,807,200
Total Current Liabilities  (calculated)1,807,200
+/-0
Long-term Liabilities
Long term Debt 161,900
Other Liabilities 371,300
Long-term Liabilities Other 51,600
Long-term Liabilities  (as reported)533,200
Long-term Liabilities  (calculated)584,800
+/- 51,600
Total Stockholder Equity
Common Stock248,600
Retained Earnings 19,305,400
Other Stockholders Equity 323,600
Total Stockholder Equity (as reported)19,866,800
Total Stockholder Equity (calculated)19,877,600
+/- 10,800
Other
Capital Stock248,600
Common Stock Shares Outstanding 237,716
Net Invested Capital 20,068,700
Net Tangible Assets 18,835,700
Net Working Capital 16,941,900
Property Plant and Equipment Gross 925,900



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-30
> Total Assets 
722,369
738,408
797,647
732,208
973,447
1,449,252
2,318,620
4,204,700
9,148,800
14,232,600
15,830,800
20,299,600
21,155,400
22,660,600
23,279,100
22,079,000
22,225,600
22,207,200
22,207,20022,225,60022,079,00023,279,10022,660,60021,155,40020,299,60015,830,80014,232,6009,148,8004,204,7002,318,6201,449,252973,447732,208797,647738,408722,369
   > Total Current Assets 
504,322
501,295
560,151
492,855
621,116
1,091,839
1,666,896
3,536,000
8,439,500
13,551,400
15,072,300
19,466,100
20,208,100
21,268,800
21,922,000
20,086,100
19,213,900
18,749,100
18,749,10019,213,90020,086,10021,922,00021,268,80020,208,10019,466,10015,072,30013,551,4008,439,5003,536,0001,666,8961,091,839621,116492,855560,151501,295504,322
       Cash And Cash Equivalents 
284,890
463,308
519,149
451,597
573,011
990,461
1,210,209
891,500
914,100
2,392,700
1,692,700
6,164,100
9,334,800
13,423,700
13,875,100
12,143,900
14,166,600
13,495,800
13,495,80014,166,60012,143,90013,875,10013,423,7009,334,8006,164,1001,692,7002,392,700914,100891,5001,210,209990,461573,011451,597519,149463,308284,890
       Short-term Investments 
190,646
356
1,680
1,723
1,953
17,843
137,234
500
800
1,800
381,600
900
100
4,800
189,400
358,000
1,390,700
2,253,300
2,253,3001,390,700358,000189,4004,800100900381,6001,800800500137,23417,8431,9531,7231,680356190,646
       Net Receivables 
8,858
8,931
20,734
12,481
10,312
7,894
166,366
2,396,000
7,052,600
10,604,800
12,382,100
12,696,200
10,383,300
7,309,800
7,145,600
6,450,500
2,657,900
2,298,100
2,298,1002,657,9006,450,5007,145,6007,309,80010,383,30012,696,20012,382,10010,604,8007,052,6002,396,000166,3667,89410,31212,48120,7348,9318,858
       Inventory 
7,279
10,869
12,073
9,629
8,615
12,368
64,120
146,900
305,400
393,400
502,500
459,300
367,700
294,800
439,600
424,100
448,900
415,700
415,700448,900424,100439,600294,800367,700459,300502,500393,400305,400146,90064,12012,3688,6159,62912,07310,8697,279
       Other Current Assets 
7,477
9,345
6,515
17,425
27,225
63,273
88,967
101,100
166,600
158,700
113,400
145,600
122,200
235,700
271,900
171,300
212,300
286,200
286,200212,300171,300271,900235,700122,200145,600113,400158,700166,600101,10088,96763,27327,22517,4256,5159,3457,477
   > Long-term Assets 
218,047
237,113
237,496
239,353
352,331
357,413
651,724
668,700
709,300
681,200
758,500
833,500
947,300
1,391,800
1,357,100
1,992,900
3,011,700
3,458,100
3,458,1003,011,7001,992,9001,357,1001,391,800947,300833,500758,500681,200709,300668,700651,724357,413352,331239,353237,496237,113218,047
       Property Plant Equipment 
0
142,631
148,062
145,421
167,734
183,503
325,956
360,800
381,100
442,100
520,400
556,900
664,100
760,500
821,100
847,600
894,000
925,900
925,900894,000847,600821,100760,500664,100556,900520,400442,100381,100360,800325,956183,503167,734145,421148,062142,6310
       Goodwill 
0
0
2,978
0
0
0
53,697
0
0
0
57,800
0
0
0
61,200
0
0
365,600
365,6000061,20000057,80000053,6970002,97800
       Long Term Investments 
1
0
0
0
0
0
0
0
0
0
21,300
48,400
51,500
52,800
80,200
516,800
1,374,300
1,292,700
1,292,7001,374,300516,80080,20052,80051,50048,40021,3000000000001
       Intangible Assets 
0
0
86,456
0
0
0
109,793
0
0
0
144,600
0
0
0
158,500
0
0
665,500
665,50000158,500000144,600000109,79300086,45600
       Long-term Assets Other 
218,047
237,113
2
239,353
1,316
5,177
1,045
1,000
900
900
800
800
900
1,100
6,500
4,400
2,500
300
3002,5004,4006,5001,1009008008009009001,0001,0455,1771,316239,3532237,113218,047
> Total Liabilities 
337,879
322,003
304,155
284,078
371,513
521,569
946,774
1,685,100
3,666,000
5,521,100
3,937,100
4,388,900
4,324,700
4,294,300
3,223,500
1,813,700
2,319,100
2,340,400
2,340,4002,319,1001,813,7003,223,5004,294,3004,324,7004,388,9003,937,1005,521,1003,666,0001,685,100946,774521,569371,513284,078304,155322,003337,879
   > Total Current Liabilities 
135,993
128,123
138,142
142,043
208,566
268,480
606,014
1,311,100
3,163,300
4,902,600
3,481,600
3,854,500
3,923,700
3,957,700
2,950,600
1,550,900
1,819,000
1,807,200
1,807,2001,819,0001,550,9002,950,6003,957,7003,923,7003,854,5003,481,6004,902,6003,163,3001,311,100606,014268,480208,566142,043138,142128,123135,993
       Short Long Term Debt 
0
0
0
0
0
0
9,142
18,000
13,900
19,000
129,900
30,600
32,300
37,000
36,000
37,400
38,600
40,000
40,00038,60037,40036,00037,00032,30030,600129,90019,00013,90018,0009,142000000
       Accounts payable 
16,881
21,813
20,498
19,417
35,690
41,912
102,288
106,200
262,700
258,900
160,000
123,700
291,100
296,500
204,100
29,900
228,600
222,700
222,700228,60029,900204,100296,500291,100123,700160,000258,900262,700106,200102,28841,91235,69019,41720,49821,81316,881
       Other Current Liabilities 
29,013
22,577
105,626
117,936
166,176
223,624
494,584
1,186,900
2,886,700
4,624,700
3,191,700
3,700,200
3,600,300
3,624,200
1,645,900
534,700
420,900
1,544,500
1,544,500420,900534,7001,645,9003,624,2003,600,3003,700,2003,191,7004,624,7002,886,7001,186,900494,584223,624166,176117,936105,62622,57729,013
   > Long-term Liabilities 
201,886
193,880
166,013
142,035
162,947
253,089
340,760
374,000
502,700
618,500
455,500
534,400
401,000
336,600
272,900
262,800
500,100
533,200
533,200500,100262,800272,900336,600401,000534,400455,500618,500502,700374,000340,760253,089162,947142,035166,013193,880201,886
       Other Liabilities 
0
126,067
97,109
75,394
92,658
92,494
109,713
137,400
259,800
350,800
283,900
379,000
194,400
99,600
0
0
0
371,300
371,30000099,600194,400379,000283,900350,800259,800137,400109,71392,49492,65875,39497,109126,0670
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
13,600
11,400
9,400
7,500
0
0
0
0
00007,5009,40011,40013,6000000000000
> Total Stockholder Equity
384,490
416,405
493,492
448,130
601,934
927,683
1,371,846
2,519,600
5,482,800
8,711,500
11,893,700
15,910,700
16,830,700
18,366,300
20,055,600
20,265,300
19,906,500
19,866,800
19,866,80019,906,50020,265,30020,055,60018,366,30016,830,70015,910,70011,893,7008,711,5005,482,8002,519,6001,371,846927,683601,934448,130493,492416,405384,490
   Common Stock
0
221,787
232,304
232,304
238,198
246,310
246,310
246,300
246,300
246,300
246,300
246,800
248,600
248,600
0
0
0
248,600
248,600000248,600248,600246,800246,300246,300246,300246,300246,310246,310238,198232,304232,304221,7870
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
566,747
691,540
699,564
935,770
1,463,439
1,539,954
1,559,600
1,734,600
1,752,300
1,768,300
2,086,000
1,818,600
1,573,700
0
0
0
323,600
323,6000001,573,7001,818,6002,086,0001,768,3001,752,3001,734,6001,559,6001,539,9541,463,439935,770699,564691,540566,7470



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue6,618,300
Cost of Revenue-2,319,300
Gross Profit4,299,0004,299,000
 
Operating Income (+$)
Gross Profit4,299,000
Operating Expense-2,852,700
Operating Income3,765,6001,446,300
 
Operating Expense (+$)
Research Development-
Selling General Administrative556,300
Selling And Marketing Expenses-
Operating Expense2,852,700556,300
 
Net Interest Income (+$)
Interest Income276,000
Interest Expense-3,900
Other Finance Cost-2,700
Net Interest Income269,400
 
Pretax Income (+$)
Operating Income3,765,600
Net Interest Income269,400
Other Non-Operating Income Expenses-
Income Before Tax (EBT)3,695,5004,105,100
EBIT - interestExpense = -3,900
2,751,100
2,755,000
Interest Expense3,900
Earnings Before Interest and Taxes (EBIT)-3,699,400
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax3,695,500
Tax Provision-944,400
Net Income From Continuing Ops2,751,1002,751,100
Net Income2,751,100
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-339,500-269,400
 

Technical Analysis of Biontech
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biontech. The general trend of Biontech is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biontech's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioNTech SE.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 89.78 < 89.98 < 92.54.

The bearish price targets are: 80.60 > 77.50.

Tweet this
BioNTech SE Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioNTech SE. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioNTech SE Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioNTech SE. The current macd is -0.3103367.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biontech price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Biontech. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Biontech price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
BioNTech SE Daily Moving Average Convergence/Divergence (MACD) ChartBioNTech SE Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioNTech SE. The current adx is 17.03.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Biontech shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
BioNTech SE Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioNTech SE. The current sar is 88.38.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BioNTech SE Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioNTech SE. The current rsi is 49.58. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
BioNTech SE Daily Relative Strength Index (RSI) ChartBioNTech SE Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioNTech SE. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biontech price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
BioNTech SE Daily Stochastic Oscillator ChartBioNTech SE Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioNTech SE. The current cci is 50.78.

BioNTech SE Daily Commodity Channel Index (CCI) ChartBioNTech SE Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioNTech SE. The current cmo is 1.64636639.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BioNTech SE Daily Chande Momentum Oscillator (CMO) ChartBioNTech SE Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioNTech SE. The current willr is -36.15635179.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Biontech is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BioNTech SE Daily Williams %R ChartBioNTech SE Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BioNTech SE.

BioNTech SE Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioNTech SE. The current atr is 2.91029416.

BioNTech SE Daily Average True Range (ATR) ChartBioNTech SE Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioNTech SE. The current obv is 111,191.

BioNTech SE Daily On-Balance Volume (OBV) ChartBioNTech SE Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioNTech SE. The current mfi is 80.37.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
BioNTech SE Daily Money Flow Index (MFI) ChartBioNTech SE Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioNTech SE.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-13 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-21 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-04 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-21 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-15 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-23 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-26 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-01 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside

6.3. Candlestick Patterns

BioNTech SE Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioNTech SE based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.577
Ma 20Greater thanMa 5084.977
Ma 50Greater thanMa 10086.094
Ma 100Greater thanMa 20089.893
OpenGreater thanClose84.820
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biontech with someone you think should read this too:
  • Are you bullish or bearish on Biontech? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biontech? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioNTech SE

I send you an email if I find something interesting about BioNTech SE.


Comments

How you think about this?

Leave a comment

Stay informed about BioNTech SE.

Receive notifications about BioNTech SE in your mailbox!